Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children

By Raz R.   Dagan R.   Gallil A.   Brill G.   Kassis I.   Koren R.  

Vaccine, Vol. 14, Iss. 3, 1996-02 ,pp. : 207-211

Elsevier

Access to resources Recommend Favorite

Astounding influence of 'substance abuse', malnutrition and immune suppression on immune response to hepatitis B vaccine

By Arya S.C.  

Vaccine, Vol. 13, Iss. 9, 1995-06 ,pp. : 879-879

Elsevier

Access to resources Recommend Favorite

T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice

By Jones C.D.   Page M.   Bacon A.   Cahill E.   Bentley M.   Chatfield S.N.  

Vaccine, Vol. 17, Iss. 20, 1999-06 ,pp. : 2528-2537

Elsevier

Access to resources Recommend Favorite

Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection

By Chen X.   Li M.   Le X.   Ma W.   Zhou B.  

Vaccine, Vol. 22, Iss. 3, 2004-01 ,pp. : 439-446

Elsevier

Access to resources Recommend Favorite

Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults

By Leroux-Roels G.   Desombere I.   De Tollenaere G.   Petit M.-A.   Desmons P.   Hauser P.   Delem A.   De Grave D.   Safary A.  

Vaccine, Vol. 15, Iss. 16, 1997-11 ,pp. : 1724-1731

Elsevier

Access to resources Recommend Favorite